A Phase 1 interventional study of Menopausal hormone therapy in Menopause and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by University of Oxford · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford — 1 open to participants now, 3 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · University of Oxford.
Among the 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford, this one is the only one that started in 2025, is one of 2 in phase 1, and was the 10th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →1 of the 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford is open now, in 1 country.
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 40 across the 7 interventional studies, 40 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
1 of the studies in Non-alcoholic Fatty Liver Disease by University of Oxford that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04227782University of OxfordMRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH) | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Non-alcoholic Fatty Liver Disease by University of Oxford, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, currently affecting approximately 1-in-4 people globally. The prevalence is expected to rise further, driven at least partly by the epidemic of obesity and diabetes. MASLD is a condition of fat build-up in the liver that can progress to liver scarring which is associated with higher chances of death. Women are more than twice as likely to develop MASLD after menopause compared to before menopause, and previous research has shown that this may be caused by a lack of oestrogen. A lack of oestrogen is also believed to lead to harmful changes in adipose (body fat), which has an important role in the development of MASLD. Oestrogen contained in hormone replacement therapy (HRT) is an effective treatment for hot flushes and other problems in menopause. The popularity of HRT has increased dramatically in the United Kingdom in recent years, however the exact way in which it affects adipose and MASLD is unclear. The investigators will study how HRT affects the processes that drive MASLD in 10 women before and after using the treatment. This is a small-scale pilot study to understand feasibility of recruitment and test the procedures for a future, larger-scale studies.
The investigators will recruit women who are about to begin HRT for the first time and perform the same tests for each participant before starting HRT, and after using HRT for 12-weeks. The participants will undergo meal testing including non-radioactive, stable isotopes, and blood and breath samples will be collected to measure fat processing. The total fat content of the liver will be measured using magnetic resonance imaging (MRI) scans. Adipose samples will be collected, fat metabolites will be measured and the distribution of fat around the body will be assessed using a dual energy x-ray absorptiometry (DEXA) scan. To find out how HRT affects these processes, the results from before and after using HRT will be compared. Understanding how HRT affects adipose and the liver may help reduce the development of MASLD in women after the menopause and improve their health and survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
status:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants starting any brand, composition, route and dose of oestrogen-based systemic hormone replacement therapy, will be included in this group.
Drug: Menopausal hormone therapy
Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen. Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)
Recruitment into an experimental medicine study investigating the impact of HRT on MASLD
Number of participants who are screened and recruited into the study
Time frame: 7 months
Acceptability of experimental protocols in experimental medicine study investigating the impact of HRT on MASLD
Feedback from questionnaire completed by study participants
Time frame: From enrollment to the end of the study after completing 12 weeks of intervention
Participant retention in an experimental medicine study investigating the impact of HRT on MASLD
Number of participants who complete the study (per protocol)
Time frame: From enrollment to the end of the study after completing 12 weeks of intervention
Fatty acid esterification into triglyceride
Measurement of 13C-palmitate incorporation into very low density lipoprotein triglyceride (VLDL-TG)
Time frame: Performed at baseline and after 12 weeks of intervention
Hepatic lipid content
Measurement of intrahepatic triglyceride content by magnetic resonance imaging / spectroscopy
Time frame: At baseline and after 12 weeks of intervention
Whole body fatty acid oxidation
Measurement of incorporation of 13C into breath CO2 using GC-C-IRMS.
Time frame: At baseline and after 12 weeks of intervention
Fasting and postprandial plasma intrahepatic fatty acid synthesis.
Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate (via 2H2O) into VLDL-TG
Time frame: At baseline and after 12 weeks of intervention
Liver profile blood tests and circulating lipid profiles
Routine laboratory biochemistry
Time frame: At baseline and after 12 weeks of intervention
Interstitial levels of metabolites in adipose tissue
Change in adipose tissue metabolite profile
Time frame: At baseline and after 12 weeks of intervention
Adipose tissue transcriptomic profile
Change in adipose tissue transcriptomic profile in abdominal subcutaneous and gluteal depots
Time frame: At baseline and after 12 weeks of intervention
Total and regional lean and fat tissue distribution
Total and regional lean and fat mass on Dual energy X-ray absorptiometry (DXA) scan
Time frame: At baseline and after 12 weeks of intervention
Adipose tissue steroid profile
Adipose tissue steroid profile
Time frame: At baseline and after 12 weeks of intervention
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Aug 2025, 7 months later.
Of 125 phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →